Active Filter(s):
Details:
Acquisition expands Lilly's R&D efforts in pain and neurodegeneration with the addition of Disarm's promising preclinical SARM1 programs for axonal degeneration .
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $1,360.0 million Upfront Cash: $135.0 million
Deal Type: Acquisition October 15, 2020